ZZ Biotech, LLC

Belkins
ZZ Biotech LLC is a clinical stage company developing innovative biologic treatments for ischemic stroke and other neurological diseases and wound healing applications including the treatment of diabetic foot ulcers. ZZ Biotech was incepted in 2006 to focus on the development of 3K3A-APC, a novel second-generation variant of a naturally occurring human protein licensed from The Scripps Research Institute. ZZ Biotech’s 3K3A-APC is a genetically engineered variant of recombinant APC, a serine protease. APC has two biochemical pathways in the body. APC exerts anticoagulant activity by inactivation of Factor Va and VIIIa, and it exerts cytoprotective activity primarily through interaction with the endothelial protein C receptor (EPCR) and protease-activated receptor-1 (PAR-1). 3K3A-APC was designed through elegant biochemistry and molecular biology as a safer, “bio-better” version of APC, with greatly reduced anti-coagulant activity.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

ANOTHER TAKEDA/SHIRE R&D EXEC JUMPS SHIP AS PHARVARIS NABS PENG LU AS ITS NEW CMO

FierceBiotech | February 07, 2020

news image

After getting off a $66 million series B round in September last year, hereditary angioedema (HAE) specialist Pharvaris has taken on a seasoned HAE developer to help lead its pipeline. The startup has nabbed former Takeda/Shire exec Peng Lu, M.D., Ph.D., as its chief medical officer; Lu comes from Shire after it has been subsumed into Japanese Big Pharma Takeda and follows a whole host of other execs who have hit the exit amid the merger. At Shire, she led the team that finished up the phase 3 p...

Read More

BOOST BIOMES ANNOUNCES CLOSE OF SERIES A AND CO-DEVELOPMENT AGREEMENT WITH LEAD INVESTOR, YARA INTERNATIONAL, FOR BIOSTIMULANTS PRODUCTS

Boost Biomes | June 25, 2020

news image

US-based food and agriculture biotech startup Boost Biomes and global crop nutrition company, Yara International ASA, announced today the close of Boost's USD 5 million series A equity round as well as a joint development agreement between the two companies. Yara's investment amounts to USD 3 million. Existing investors, including Viking Global Investors and Y Combinator, participated in the close.With this partnership in place, Boost and Yara will expand current efforts to co-deve...

Read More

AVM BIOTECHNOLOGY HIRES EXECUTIVE TEAM FOR ONCOLOGY & COVID-19 CLINICAL TRIALS

AVM Biotechnology | July 09, 2020

news image

Seattle's AVM Biotechnology, an up-and-coming biotech firm whose lead molecule, AVM0703, has received FDA permission to begin clinical trials treating no-option Non-Hodgkin's Lymphoma and is applying to begin trials treating moderate-severely ill COVID-19 patients, announced today the hiring of Janet R. Rea, MSPH, as Chief Operating Officer. As COO, Rea will lead operations and direct regulatory affairs as the company conducts clinical trials and brings AVM0703 to market."I am...

Read More

ANIXA BIOSCIENCES TO FOCUS ON DEVELOPMENT AND EXPANSION OF ITS THERAPEUTICS AND VACCINE PORTFOLIO

Anixa Biosciences | July 03, 2020

news image

Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, today announced that it has strategically realigned its business focus and redirected resources to exclusively focus on the development of therapeutics and vaccines in high-need patient populations. As part of this realignment, the company has suspended development of the Cchek™ liquid biopsy technology.Going forward, Anixa's operations ...

Read More
news image

ANOTHER TAKEDA/SHIRE R&D EXEC JUMPS SHIP AS PHARVARIS NABS PENG LU AS ITS NEW CMO

FierceBiotech | February 07, 2020

After getting off a $66 million series B round in September last year, hereditary angioedema (HAE) specialist Pharvaris has taken on a seasoned HAE developer to help lead its pipeline. The startup has nabbed former Takeda/Shire exec Peng Lu, M.D., Ph.D., as its chief medical officer; Lu comes from Shire after it has been subsumed into Japanese Big Pharma Takeda and follows a whole host of other execs who have hit the exit amid the merger. At Shire, she led the team that finished up the phase 3 p...

Read More
news image

BOOST BIOMES ANNOUNCES CLOSE OF SERIES A AND CO-DEVELOPMENT AGREEMENT WITH LEAD INVESTOR, YARA INTERNATIONAL, FOR BIOSTIMULANTS PRODUCTS

Boost Biomes | June 25, 2020

US-based food and agriculture biotech startup Boost Biomes and global crop nutrition company, Yara International ASA, announced today the close of Boost's USD 5 million series A equity round as well as a joint development agreement between the two companies. Yara's investment amounts to USD 3 million. Existing investors, including Viking Global Investors and Y Combinator, participated in the close.With this partnership in place, Boost and Yara will expand current efforts to co-deve...

Read More
news image

AVM BIOTECHNOLOGY HIRES EXECUTIVE TEAM FOR ONCOLOGY & COVID-19 CLINICAL TRIALS

AVM Biotechnology | July 09, 2020

Seattle's AVM Biotechnology, an up-and-coming biotech firm whose lead molecule, AVM0703, has received FDA permission to begin clinical trials treating no-option Non-Hodgkin's Lymphoma and is applying to begin trials treating moderate-severely ill COVID-19 patients, announced today the hiring of Janet R. Rea, MSPH, as Chief Operating Officer. As COO, Rea will lead operations and direct regulatory affairs as the company conducts clinical trials and brings AVM0703 to market."I am...

Read More
news image

ANIXA BIOSCIENCES TO FOCUS ON DEVELOPMENT AND EXPANSION OF ITS THERAPEUTICS AND VACCINE PORTFOLIO

Anixa Biosciences | July 03, 2020

Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, today announced that it has strategically realigned its business focus and redirected resources to exclusively focus on the development of therapeutics and vaccines in high-need patient populations. As part of this realignment, the company has suspended development of the Cchek™ liquid biopsy technology.Going forward, Anixa's operations ...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us